表紙
市場調査レポート - 217929

うつ病治療薬:パイプライン評価と2018年までの市場予測

Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018

発行 GlobalData
出版日 ページ情報 英文 95 Pages
価格
うつ病治療薬:パイプライン評価と2018年までの市場予測 Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018
出版日: 2011年10月11日 ページ情報: 英文 95 Pages
概要

当レポートでは、うつ病の治療法の研究・開発の最新動向調査と、関連市場の将来予測とを実施し、病気の概要と対処法、全世界および主要7カ国における市場規模計測・予測(2005-2018年)、競争構造、臨床試験の進行状況に関するパイプライン評価、今後の市場動向や企業戦略に関する戦略的考察などの情報を盛り込んで、概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

  • 多形性神経膠芽腫の概要
  • 疫学
  • 病因および病態生理学
  • 兆候と症状
  • 診断
  • 治療・管理オプション
  • 本レポートの構成

第3章 市場の特徴

  • 市場規模計測:全世界(2005-2010年)
  • 市場規模予測:全世界(2010-2018年)
  • 市場規模計測:米国(2005-2010年)
  • 市場規模予測:米国(2010-2018年)
  • 市場規模計測:フランス(2005-2010年)
  • 市場規模予測:フランス(2010-2018年)
  • 市場規模計測:ドイツ(2005-2010年)
  • 市場規模予測:ドイツ(2010-2018年)
  • 市場規模計測:イタリア(2005-2010年)
  • 市場規模予測:イタリア(2010-2018年)
  • 市場規模計測:スペイン(2005-2010年)
  • 市場規模予測:スペイン(2010-2018年)
  • 市場規模計測:英国(2005-2010年)
  • 市場規模予測:英国(2010-2018年)
  • 市場規模計測:日本(2005-2010年)
  • 市場規模予測:日本(2010-2018年)
  • 市場促進・阻害要因
  • 今後の市場に影響する、今後の主な動向
  • 機会とアンメット・ニーズ
  • 主な結論

第4章 競争的環境

  • 概要
    • 戦略的競合企業分析
  • 主な市販製品のプロファイル
    • 選択的セロトニン再取り込み阻害薬(SSRI)
    • レクサプロ(エスシタロプラム)
    • Viibryd (ビラゾドン塩酸塩)
    • セロトニン・ノルエピネフリン再取り込み阻害薬(SNRI)
    • サインバルタ(塩酸デュロキセチン)
    • プリスティーク(コハク酸デスベンラファキシン)
    • シンビアックス(オランザピンとフルオキセチンの合剤)
  • 主な結論

第5章 パイプライン評価

  • 概要
  • 戦略的パイプライン評価
  • 開発フェーズ別パイプライン
    • フェーズIIIパイプライン
    • フェーズIIパイプライン
    • フェーズIパイプライン
    • 前臨床パイプライン
    • 技術動向分析枠組み
  • 機能メカニズム別のパイプライン
  • 治験段階にある有望な薬剤
  • 有望な薬剤の分子プロファイル
    • Lu AA21004
    • TC-5214
    • AGO178 (アゴメラチン)
  • 主な結論

第6章 治験マッピング

  • 各地域・各国における治験数(米国・EU5カ国・日本)
  • フェーズ別の治験数
  • 検証段階別の治験数
  • 有望なスポンサー
  • うつ病の治験に参加している上位企業

第7章 戦略的評価

  • 将来の市場競争シナリオ
  • 今後の市場競争への影響

第8章:今後の市場参加企業

  • イントロダクション
  • 企業プロファイル
    • Lundbeck A/S
    • Novartis AG
    • AstraZeneca PLC
    • Eli Lilly and Company
    • Targacept Inc

第9章 ライセンス・提携取引

第10章 付録

図表一覧

目次

Abstract

Summary

GlobalData, the industry analysis specialist, has released its new report, "Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global depression therapeutics market. The report identifies the key trends shaping and driving the global depression market. The report also provides insights in to the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights in to the pipeline products within the global depression market. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData valued the global depression therapeutics market at $4.6 billion in 2010, and expects it to grow at a compound annual growth rate (CAGR) of 3.2% over the next seven years to reach $10.9 billion by 2018. The depression therapeutics market will witness the patent expiry of Lexapro in 2012, Cymbalta in 2013 and Effexor XR in 2014. However, the launch of new drugs such as Viibryd, LuAA21004, Levomilnacipran (F2695) and AGO178 (in the US), offering better efficacy and safety profiles, along with disease modifying properties, will help to sustain steady and positive growth during the forecast period to 2018.

Scope

The report provides information on the key drivers and challenges of the depression market. Its scope includes -

  • Annualized global depression market revenues data from 2005 to 2010, forecast for eight years to 2018.
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as Glutamate receptor which includes Metabotropic glutamate receptors 2 antagonist, Glutamate receptor 2 and 3 antagonist, Group II metabotropic glutamate receptors antagonist, Metabotropic glutamate receptor 5 antagonist, N-methyl d-aspartate receptor (NMDAR) antagonist, Alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) potentiator whereas Seretonin receptor modulators which includes 5-HT3, 5-HT7 and 5-HT1A receptor receptor agonist and 5-HT transporter inhibitor, 5-HT3 and 5-HT2C antagonist, 5HT reuptake blockade, 5HT2 agonism, 5HT1A agonism, and 5HT1D central receptors agonist, 5-HT2A/5-HT2C/D2/D3 receptor antagonist followed by Triple-reuptake inhibitors, Monoamine oxidase (MAO) modulators, Arginine vasopressin antagonists and so on.
  • Analysis of the current and future competition in the global depression market. Key market players covered are Otsuka Holdings Co., Ltd, Forest Laboratories, H Lundbeck A/s, Eli Lilly, Targacept Inc., Fabre-Kramer Pharmaceuticals, Inc., Euthymics Bioscience, Inc., AstraZeneca PLC, and Novartis/Servier.
  • An insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the depression therapeutics market.
  • Analysis of key recent licensing and partnership agreements in the depression therapeutics market.

Reasons to buy

The report will enhance your decision making capabilities. It will allow you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global depression market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global depression market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potential strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What's the next big thing in the global depression market landscape? - Identify, understand and capitalize.

Table of contents

1. Table of contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2. Depression Therapeutics - Introduction

  • 2.1 Disease Overview
  • 2.2 Epidemiology
  • 2.3 Etiology and Pathophysiology
  • 2.4 Signs and Symptoms
  • 2.5 Diagnosis
  • 2.6 Treatment and Management Options
    • 2.6.1 Referral Pathway
  • 2.7 GlobalData Pipeline Report Guidance

3. Depression Therapeutics - Market Characterization

  • 3.1 Overview
  • 3.2 Depression Therapeutics Market Size (2005-2010) - Global
  • 3.3 Depression Therapeutics Market Forecast (2010-2018) - Global
  • 3.4 Depression Therapeutics Market Size (2005-2010) - The US
  • 3.5 Depression Therapeutics Market Forecast (2010-2018) - The US
  • 3.6 Depression Therapeutics Market Size (2005-2010) - France
  • 3.7 Depression Therapeutics Market Forecast (2010-2018) - France
  • 3.8 Depression Therapeutics Market Size (2005-2010) - Germany
  • 3.9 Depression Therapeutics Market Forecast (2010-2018) - Germany
  • 3.10 Depression Therapeutics Market Size (2005-2010) - Italy
  • 3.11 Depression Therapeutics Market Forecast (2010-2018) - Italy
  • 3.12 Depression Therapeutics Market Size (2005-2010) - Spain
  • 3.13 Depression Therapeutics Market Forecast (2010-2018) - Spain
  • 3.14 Depression Therapeutics Market Size (2005-2010) - The UK
  • 3.15 Depression Therapeutics Market Forecast (2010-2018) - The UK
  • 3.16 Depression Therapeutics Market Size (2005-2010) - Japan
  • 3.17 Depression Therapeutics Market Forecast (2010-2018) - Japan
  • 3.18 Drivers and Barriers for the Depression Therapeutics Market
    • 3.18.1 Drivers for the Depression Therapeutics Market
    • 3.18.2 Barriers for the Depression Therapeutics Market
  • 3.19 Opportunity and Unmet Need Analysis
  • 3.20 Key Takeaway

4. Depression Therapeutics: Competitive Assessment

  • 4.1 Overview
    • 4.1.1 Strategic Competitor Assessment
  • 4.2 Product Profiles for the Major Marketed Products in the Depression Therapeutics Market
    • 4.2.1 Selective Serotonin Reuptake Inhibitors (SSRIs)
    • 4.2.2 Lexapro (escitalopram)
    • 4.2.3 Viibryd (vilazodone hydrochloride)
    • 4.2.4 Serotonin-Norepinephrine Reuptake Inhibitors (SNRI)
    • 4.2.5 Cymbalta (duloxetine hydrochloride)
    • 4.2.6 Pristiq (desvenlafaxine succinate)
    • 4.2.7 Symbyax (olanzapine and fluoxetine combination)
  • 4.3 Key Takeaway

5. Depression Therapeutics - Pipeline Assessment

  • 5.1 Overview
  • 5.2 Strategic Pipeline Assessment
  • 5.3 Depression Therapeutics Pipeline - Pipeline by Phases of Development
    • 5.3.1 Depression Therapeutics - Phase III Pipeline
    • 5.3.2 Depression Therapeutics - Phase II Pipeline
    • 5.3.3 Depression Therapeutics - Phase I Pipeline
    • 5.3.4 Depression Market - Pre-Clinical Pipeline
    • 5.3.5 Technology Trends Analytic Framework
  • 5.4 Depression Therapeutics Market -Pipeline by Mechanism of Action
  • 5.5 Depression Therapeutics - Promising Drugs under Clinical Development
  • 5.6 Molecule Profile for Promising Drugs Under Clinical Development
    • 5.6.1 Lu AA21004
    • 5.6.2 TC-5214
    • 5.6.3 AGO178 (agomelatine)
  • 5.7 Key Takeaway

6. Depression Therapeutics - Clinical Trials Mapping

  • 6.1 Clinical Trials by Region/Country (US, EU5 and Japan)
  • 6.2 Clinical Trials by Phase
  • 6.3 Clinical Trials by Trial Status
  • 6.4 Prominent Sponsors
  • 6.5 Top Companies Participating in Depression Therapeutics Clinical Trials

7. Strategic Assessment

  • 7.1 Key Events Impacting the Future Market
  • 7.2 Depression Therapeutics: Implications for Future Market Competition

8. Depression Therapeutics: Future Players

  • 8.1 Introduction
  • 8.2 Company Profiles
    • 8.2.1 Lundbeck A/S
    • 8.2.2 Novartis AG
    • 8.2.3 AstraZeneca PLC
    • 8.2.4 Eli Lilly and Company
    • 8.2.5 Targacept Inc.

9. Depression Therapeutics - Licensing and Partnership Deals

10. Depression Therapeutics - Appendix

  • 10.1 Market Definitions
  • 10.2 Abbreviations
  • 10.3 Methodology
    • 10.3.1 Coverage
    • 10.3.2 Secondary Research
    • 10.3.3 Forecasting
    • 10.3.4 Primary Research
    • 10.3.5 Expert Panel Validation
  • 10.4 Contact Us
  • 10.5 Disclaimer
  • 10.6 Bibliography

List of Tables

  • Table 1: Stages of Depression
  • Table 2: Depression Therapeutics Market, Global, Revenue ($bn), 2005-2010
  • Table 3: Depression Therapeutics Market, Global, Forecast ($bn), 2010-2018
  • Table 4: Depression Therapeutics Market, The US, Revenue ($m), 2005-2010
  • Table 5: Depression Therapeutics Market, The US, Forecast ($m), 2010-2018
  • Table 6: Depression Therapeutics Market, France, Revenue ($m), 2005-2010
  • Table 7: Depression Therapeutics Market, France, Forecast ($m), 2010-2018
  • Table 8: Depression Therapeutics Market, Germany, Revenue ($m), 2005-2010
  • Table 9: Depression Therapeutics Market, Germany, Forecast ($m), 2010-2018
  • Table 10: Depression Therapeutics Market, Italy, Revenue ($m), 2005-2010
  • Table 11: Depression Therapeutics Market, Italy, Forecast ($m), 2010-2018
  • Table 12: Depression Therapeutics Market, Spain, Revenue ($m), 2005-2010
  • Table 13: Depression Therapeutics Market, Spain, Forecast ($m), 2010-2018
  • Table 14: Depression Therapeutics Market, The UK, Revenue ($m), 2005-2010
  • Table 15: Depression Therapeutics Market, The UK, Forecast ($m), 2010-2018
  • Table 16: Depression Therapeutics Market, Japan, Revenue ($m), 2005-2010
  • Table 17: Depression Therapeutics Market, Japan, Forecast ($m), 2010-2018
  • Table 18: SSRIs Approved for Depression
  • Table 19: Summary of Results for the Primary Efficacy Endpoint
  • Table 20: SNRIs Approved for Depression
  • Table 21: MADRS Total Score Mean Change from Baseline to Endpoint
  • Table 22: Depression Therapeutics, Phase III Pipeline, 2011
  • Table 23: Depression Therapeutics, Phase II Pipeline, 2011
  • Table 24: Depression Therapeutics, Phase I Pipeline, 2011
  • Table 25: Depression Therapeutics, Pre-clinical Pipeline, 2011
  • Table 26: Depression Therapeutics - Most Promising Drugs Under Clinical Development, 2011
  • Table 27: Lu AA21004 Efficacy Measure
  • Table 28: Treatment-Related Adverse Events
  • Table 29: AGO178, Active Comparator Study
  • Table 30: Depression Therapeutics, Clinical Trials by Country, 2011
  • Table 31: Depression Therapeutics, Clinical Trials by Phase, 2011
  • Table 32: Depression Therapeutics, Clinical Trials by Status, 2011
  • Table 33: Depression Therapeutics, Overall Sponsors, 2011
  • Table 34: Depression Therapeutics, Prominent Sponsors, 2011
  • Table 35: Depression Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011
  • Table 36: Lundbeck A/S - Depression, Pipeline Products, 2011
  • Table 37: Novartis, Depression Pipeline, 2011
  • Table 38: AstraZeneca PLC, Depression Pipeline, 2011
  • Table 39: Eli Lilly and Company, Depression Pipeline, 2011
  • Table 40: Targacept Inc., Depression Pipeline, 2011
  • Table 41: Depression Therapeutics, Global, Deals, 2009-2011

List of Figures

  • Figure 1: DSM-IV Diagnostic Criteria for Depression
  • Figure 2: Total Estimated Cost of Brain Disorders in Europe by Disease Area
  • Figure 3: Economic Burden Associated with Depression
  • Figure 4: Relationship Between Major Depression and Cardiovascular Disease
  • Figure 5: Serotonergic Systems in Alteration of Depression
  • Figure 6: Alterations of Noradrenergic Systems in Depression
  • Figure 7: Alterations of Dopaminergic Systems in Depression
  • Figure 8: Diagnostic Approach for Depression
  • Figure 9: Drug Classes for the Treatment of Depression
  • Figure 10: Treatment Algorithm
  • Figure 11: Referral Pathway for Depression
  • Figure 12: Depression Therapeutics Market, Global, Revenue ($bn), 2005-2010
  • Figure 13: Depression Therapeutics Market, Global, Forecast ($bn), 2010-2018
  • Figure 14: Depression Therapeutics Market, The US, Revenue ($m), 2005-2010
  • Figure 15: Depression Therapeutics Market, The US, Forecast ($m), 2010-2018
  • Figure 16: Depression Therapeutics Market, France, Revenue ($m), 2005-2010
  • Figure 17: Depression Therapeutics Market, France, Forecast ($m), 2010-2018
  • Figure 18: Depression Therapeutics Market, Germany, Revenue ($m), 2005-2010
  • Figure 19: Depression Therapeutics Market, Germany, Forecast ($m), 2010-2018
  • Figure 20: Depression Therapeutics Market, Italy, Revenue ($m), 2005-2010
  • Figure 21: Depression Therapeutics Market, Italy, Forecast ($m), 2010-2018
  • Figure 22: Depression Therapeutics Market, Spain, Revenue ($m), 2005-2010
  • Figure 23: Depression Therapeutics Market, Spain, Forecast ($m), 2010-2018
  • Figure 24: Depression Therapeutics Market, The UK, Revenue ($m), 2005-2010
  • Figure 25: Depression Therapeutics Market, The UK, Forecast ($m), 2010-2018
  • Figure 26: Depression Therapeutics Market, Japan, Revenue ($m), 2005-2010
  • Figure 27: Depression Therapeutics Market, Japan, Forecast ($m), 2010-2018
  • Figure 28: Opportunity and Unmet Need in the Depression Therapeutics Market, 2010
  • Figure 29: Depression Therapeutics, Strategic Competitor Assessment, 2010
  • Figure 30: Depression Therapeutics, Pipeline by Phase of Development, 2011
  • Figure 31: Approaches to the Development of Antidepressants Targeting Non Monoaminergic Components
  • Figure 32: Depression Therapeutics, Technology Trends Analytical Framework, 2011
  • Figure 33: Depression Therapeutics, Technology Trends Analytical Framework, Description, 2011
  • Figure 34: Depression Therapeutics, Pipeline by Mechanism of Action (%), 2011
  • Figure 35: Depression Therapeutics, Clinical Trials by Country, 2011
  • Figure 36: Depression Therapeutics, Clinical Trials by Phase (%), 2011
  • Figure 37: Depression Therapeutics, Clinical Trials by Status (%), 2011
  • Figure 38: Depression Therapeutics, Overall Sponsors (%), 2011
  • Figure 39: Depression Therapeutics, Prominent Sponsors (%), 2011
  • Figure 40: Depression Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011
  • Figure 41: Depression Therapeutics Market, Drivers and Barriers, 2011
  • Figure 42: Implications for Future Market Competition in the Depression Market, 2011
  • Figure 43: Depression Therapeutics Market - Pipeline by Company, 2011
  • Figure 44: GlobalData Market Forecasting Model
Back to Top